In “AAV-mediated gene therapy for Choroideremia: Preclinical studies in personalized in vitro models”, by Vasireddy et al (DOI:
In the corrected version of
hCHM. I). Schematic of the AAV proviral plasmid carrying human
I). Schematic of the AAV proviral plasmid carrying human
Lane 12 contains a protein marker (SeeBlue Plus2, Invitrogen, Grand Island, NY), lanes 2–6 and 9–10 show results of loading 25 μg of CHO cell lysate after replicate transfections with pAAV2.hCHM, and lane 1 was blank. Lanes 7, 8 and 11 show untreated control CHO cell lysates. Lysates from cells that were floating after transfection are shown in lanes 3 and 6. **Lanes 4, 7, and 12 were presented in
(TIF)
Lanes 1, 3, 4, and 6 contained lysates of CHO cells infected with 1E4, 1E5, 2E5 and 1E3 vg of AAV2.hCHM, respectively. Lane 5 is a positive control (pAAV2.hCHM-transfected CHO cell lysate). Lane 2 was not used and lane 7 was lysate from untreated CHO cells. Lanes 8 and 9 contained samples from an unrelated experiment and lane 10 contained the SeeBlue Plus2 protein marker. **Lanes 6, 1, 3, 4, 5, 7, 10 were presented in
(TIF)